Mangoselect®: Characterization, Pharmacokinetics and Bioavailability of Xanthone Metabolites

Evaluation of Absorption and Metabolism of Phenolic Compounds From Mangoselect®, an Extract of Mangosteen. Comparison of Two Versions During a Randomized, Double-blinded and Cross-over Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04151641

Enrollment

Registered

2019-11-05

Start date

2019-11-11

Completion date

2019-12-17

Last updated

2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Modification

Brief summary

The aim of this study is to compare pharmacokinetics and bioavailability of phenolic compounds, mainly xanthones, from a mangosteen extract, either ingested in a dry powder form or in an encapsulated form. Absorption and metabolism will be determined by measuring urinary excretion of phenolic metabolites and blood metabolic profile over 72 hours by means of High Pressure Liquid Chromatography (HPLC) coupled with tandem mass spectroscopy. The design of this study is a cross-over, double-blind and randomized trial on 10 healthy subjects.

Interventions

DIETARY_SUPPLEMENTMNGDPF

Standardized mangosteen extract in dry powder form

DIETARY_SUPPLEMENTMNGEF

Standardized mangosteen extract in encapsulated form

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SCREENING

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Provision of signed and dated informed consent study * Stated willingness to comply with all the study procedures and availability for the duration of the study * Male and female * Normal BMI range (18.50-24.99) * In good general health as evidenced by medical history * Ability to take oral medication and be willing to adhere to lifestyle considerations

Exclusion criteria

* Current use of any medication or food supplement * Pregnancy or lactation * Known allergic reaction to mangosteen * Metabolic disorders or any kind of disease * Currant smoker

Design outcomes

Primary

Measure	Time frame	Description
Difference in urinary metabolites excretion between MNGDPF (Mangoselect dry powder form) and MNGEF (Mangoselect encapsulated form)	Baseline (post-ingestion), 0-3 hours, 3-6 hours, 6-10 hours, 10-14 hours, 14-24 hours, 24-48 hours, 48-72 hours	Urine samples will be collected in baseline and up to 72h after ingestion of the supplement according to the time frame. Urinary metabolites will be identified and quantified by High Pressure Liquid Chromatography-Mass spectrometry (HPLC-MS).

Secondary

Measure	Time frame	Description
Difference in plasma concentration of phenolic metabolites between MNGDPF and MNGEF	Baseline (post-ingestion), 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 19 hours, 24 hours, 48 hours	Plasma samples will be collected in baseline and up to 48h after ingestion of the supplement according to the time frame. Plasma metabolites will be identified and quantified by HPLC-MS.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026